108 results
Page 2 of 6
8-K
EX-99.1
9oplliz14k59pop
4 Aug 22
BeiGene Reports Second Quarter 2022 Financial Results
7:08am
8-K
EX-99.1
piq556
14 Jun 22
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
5:16pm
8-K
EX-99.1
sja6tjs
27 May 22
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
8:33am
8-K
EX-99.1
ppi 3vq5jnyme3ogpc
5 May 22
BeiGene Reports First Quarter 2022 Financial Results
7:06am
8-K
EX-10.1
2lh21n 3an7p00nv687
22 Feb 22
BRUKINSA was granted approval by the European Commission for the treatment of Waldenström’s macroglobulinemia in November 2021
4:10pm
8-K
EX-99.1
pkp1w08oc
2 Feb 22
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors
4:12pm
8-K
EX-99.1
90oxrkuwfc9r5x 47fo
10 Jan 22
China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
7:38am
8-K
EX-99.2
lg0ysbsx
6 Dec 21
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
4:16pm
424B5
o6jhw m1t
1 Dec 21
Prospectus supplement for primary offering
5:07pm
424B5
iwo3cdnvphzl cqo
23 Nov 21
Prospectus supplement for primary offering
5:14pm
8-K
EX-99.1
sf1fxhf
26 Aug 21
Other Events
4:19pm
8-K
EX-99.1
411gfmg6
5 Aug 21
BeiGene Reports Second Quarter 2021 Financial Results
4:48pm
8-K
EX-99.2
l5x r35e2hwlz
30 Jul 21
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
7:39am